Diabetes: Too Many Drugs? Too Many Guidelines?

Dr. Claire Stocker
Senior Research Fellow, Clore Life Sciences, University of Buckingham


Claire was awarded her BSc (Hons) Biochemistry from the University of Southampton and a PhD from Imperial College, London and has worked in the pharmaceutical industry for three years. She was awarded the IASO New Investigator Award in 2002 shortly after joining the School of Science and Medicine. Claire is the Deputy Chairman for the School Ethics Committee and the Research Officer for Buckingham Institute for Translational Medicine (Clore Laboratory). In the undergraduate Medical School she is the Student Support Lead and Phase 1 Module lead for Metabolism. Claire’s main research focus is on the developmental origins of metabolic disease and potential maternal intervention strategies. Her current interests are the identification of the underlying molecular mechanisms in the regulation of energy balance both centrally and in adipose tissue. But she also has an interest in beta adrenoceptor function, insulin sensitivity in the skin and in the identification of novel metabolic targets including chemerin, AMPK and G-protein-coupled receptors. Claire holds professional membership of Developmental Origins of Health and Disease (DOHaD), European Association for the Study of Diabetes (EASD) and the Association for the Study of Obesity (UK) (ASO). She is on the Editorial board of Frontiers in Epigenomics. 



Dr Moh Tadayyon

Deputy Director, of Metabolic Research, Clore Life Sciences, University of Buckingham


Dr Moh Tadayyon has more than 20 years of healthcare industry experience in the field of metabolic disease research. He has worked in diverse areas including R&D, Medical Affairs and Commercial Strategy groups and as such has been involved across the pharma ‘value chain’ from target identification to Phase 2 clinical trials and from Phase 3b/4 planning to medico-marketing scientific strategy.

Moh has held senior research positions at SmithKline Beecham, GlaxoSmithKline and Boehringer Ingelheim, where he was a member of the Senior Management Team and the Clinical Expert Group in Metabolism and oversaw a portfolio of diabetes and obesity projects. He was directly involved in the identification of several clinical candidates for type 2 diabetes including the DPP-IV inhibitor BI1356 now on the market as linagliptin, arguably the most differentiated in the class.

Moh is currently Deputy Director of the Institute of Translational Medicine at the Clore Lab, University of Buckingham. His interests encompass novel treatment strategies for metabolic and associated diseases (hepatic steatosis, sarcopenia, heart failure and chronic kidney disease) and understanding mechanisms responsible for non-response in type 2 diabetic patients.


Dr. Stephen Lawrence

Primary Care Diabetes Advisor to Diabetes UK; Lecturer at the University of Warwick Medical School; Clinical Lead on Diabetes for the Royal College of General Practitioners


Dr. Stephen Lawrence is a Primary Care Clinical Lead in Chatham. He graduated from Leeds University Medical School in 1987. His interest in metabolic medicine was awakened when he completed a BSc (Hons) degree in Chemical Pathology during his intercalated year. He has previously worked as a Medical Advisor for Prisons at the Department of Health, where he participated in an award-winning prison diabetes study. His interests include critical appraisal of evidence-based medicine and diabetes commissioning and service development. He has presented to healthcare audiences throughout the UK and beyond. In 2003, Stephen was instrumental in establishing an intermediate-care GP with a Special Interest in Diabetes clinic in Medway in answer to the burgeoning burden of diabetes referrals to the local Medway Maritime Hospital. He has written articles on the evolving role of community-based diabetes care. He trains healthcare professionals wishing to advance to supplementary or independent prescribing status. In addition, he has served in a joint role of Primary Care Medical Advisor for Diabetes UK and Clinical Diabetes Lead for the Royal College of General Practitioners. He is a Lecturer at the University of Warwick Medical School. 


Dr. Bob Ryder

Consultant Diabetologist, Clinical Lead for Association of British Clinical Diabetologists nationwide diabetes audits, City Hospital, Birmingham


Bob Ryder went to medical school and undertook junior medical and research jobs in South Wales before moving to become Senior Registrar in Sheffield.  He has worked as a Consultant Physician with an interest in Diabetes and Endocrinology at City Hospital, Birmingham since 1991. Over the years special interests have included photographic screening for diabetic retinopathy (he undertook much of the groundwork behind the current national eye screening programme); diabetic autonomic neuropathy, diabetic impotence and . He runs the ABCD website and leads the ABCD nationwide audits of new therapies.  He is chief investigator for the NIHR supported, multicentre, ABCD Endobarrier study, “REVISE-Diabesity”, and the recently commenced “End-OSA” study of Endobarrier in diabetes with Obstructive Sleep Apnoea. A current major interest is community diabetes and a project which won the QIC best primary and/or community initiative in 2014).  Beyond diabetes he is best known for being principle author of the bestselling "An Aid to the MRCP Short Cases".


Professor Andrew Krentz

Clore Life Sciences Laboratory, University of Buckingham


Andrew Krentz (MD FRCP) is Professor of Endocrinology & Metabolism and Director of the Institute of Translational Medicine in the Clore Life Sciences Laboratory, University of Buckingham, UK. He is also Senior Research Fellow at Profil Institute for Clinical Research in San Diego, USA and a Clinical Instructor in the Department of Family & Preventive Medicine at the University of California San Diego, USA.

Senior positions have included: Visiting Professor of Medicine at Bedfordshire & Hertfordshire Postgraduate Medical School, University of Bedfordshire, UK; Consultant Physician in Diabetes & Endocrinology, Southampton University Hospitals, UK; Senior Clinical Lecturer, the University of Southampton UK.

His clinical research training in human metabolism was undertaken in Birmingham, UK and the University of New Mexico School of Medicine, Albuquerque, USA. His postgraduate doctoral thesis was titled 'Metabolic Studies in Insulin Resistance'. In 2004-5 he was the recipient of a British Heart Foundation International Research Fellow at the University of California San Diego, USA.

His textbooks include Insulin Resistance: A Clinical Handbook (2002); The Metabolic Syndrome & Cardiovascular Disease (2007); Translational Methods for Diabetes, Obesity and Cardiometabolic Drug Development: Focus on Early Phase Clinical Studies (2015). Professor Krentz has served as national Council member on the Section of Lipids, Metabolism & Vascular Disease of the Royal Society of Medicine, UK and he is accredited as a clinical specialist by the European Society for Hypertension.

He has been a member of the editorial boards of journals including Diabetes Obesity & Metabolism, Diabetes and Vascular Disease Research, Diabetic Medicine and is a faculty member at the ‘Faculty of 1000’. In 2012 he founded a new international scientific journal – Cardiovascular Endocrinology – as Editor-in-Chief.